Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Phase 2

Not yet recruiting

Conditions: FL

Interventions: Drug: Zanubrutinib
Drug: Obinutuzumab
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06474481

TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

Phase 4

Not yet recruiting

Conditions: Rejection; Transplant, Pancreas
Rejection; Transplant, Kidney

Interventions: Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: University of Sydney

Target Recruit Count: 540

Registration Number: NCT06474273

Locations: 🇨🇦
Transplant Manitoba, adult, Winnipeg, Manitoba, Canada
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Queensland Children's Hospital, South Brisbane, Queensland, Australia

and more 19 locations

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Phase 3

Recruiting

Conditions: Stage IVB Prostate Cancer AJCC v8
Castration-Resistant Prostate Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabazitaxel
Procedure: Chest Radiography
Drug: Carboplatin
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Prednisone

First Posted Date: 2024-06-24

Last Posted Date: 2024-11-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 528

Registration Number: NCT06470243

Locations: 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸
Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States

and more 170 locations

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Phase 2

Conditions: Safety Issues
Effects of Chemotherapy

Interventions: Drug: Polatuzumab Vedotin
Drug: Zanubrutinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2024-06-21

Last Posted Date: 2024-06-21

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 20

Registration Number: NCT06468943

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Nanjing, China

Prednisone for CRPS in Distal Radius Fracture

Not Applicable

Recruiting

Conditions: Complex Regional Pain Syndromes
Distal Radius Fractures

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2024-06-11

Last Posted Date: 2024-11-18

Lead Sponsor: University of British Columbia

Target Recruit Count: 40

Registration Number: NCT06453447

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Phase 2

Recruiting

Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Interventions: Drug: Tocilizumab
Drug: Prednisone

First Posted Date: 2024-06-11

Last Posted Date: 2024-07-10

Lead Sponsor: Tianjin Medical University General Hospital

Target Recruit Count: 102

Registration Number: NCT06452537

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Phase 2

Not yet recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Polatuzumab vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Acalabrutinib
Drug: Lenalidomide
Drug: Decitabine

First Posted Date: 2024-06-04

Last Posted Date: 2024-06-04

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 152

Registration Number: NCT06441097

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma, Follicular

Interventions: Drug: Golcadomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine

First Posted Date: 2024-05-22

Last Posted Date: 2024-11-19

Lead Sponsor: Celgene

Target Recruit Count: 90

Registration Number: NCT06425302

Locations: 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇩🇪
Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany
🇮🇹
Local Institution - 0179, Rozzano, Milano, Italy

and more 65 locations